Nanospectra Biosciences, Inc., a medical device company, engages in developing and commercializing particle-based therapies for the selective and precise thermal destruction of solid tumors. The company provides AuroLase Therapy, a medical device that is applicable to the ablation of various solid tumors. It also offers research-use-only nanoparticles with specific optical characteristics. Nanospectra Biosciences, Inc. was founded in 2002 and is based in Houston, Texas.

Research Grants 23 show all


$255.3K
2008

$195.4K
2009

$1.1M
2010

$445K
2011

$479.1K
2012

Patents 27show all

  • 7
    A61K - Preparations for medical, dental, or toilet purposes
  • 3
    A61N - Electrotherapy
  • 3
    B82Y - Specific uses or applications of nanostructures
  • 2
    A61B - Diagnosis
  • 2
    A61M - Devices for introducing media into, or onto, the body
  • 2
    G02C - Spectacles
  • 1
    A61F - Filters implantable into blood vessels
  • 1
    B29D - Producing particular articles from plastics or from substances in a plastic state
  • 1
    G02B - Optical elements, systems, or apparatus

Clinical Trials 4show all

4N/A

SEC Filings show all


8
D

Contact Information

8285 El Rio Street Suite 150
Houston, TX 77054
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$5,170,4651-102017-02-09Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2017-02-09$2,026,497Series Unknown
2015-12-12$945,995Series Unknown
2013-06-04$525,000Series Unknown
2014-09-08$800,000Series Unknown
2010-11-16$872,973Debt Financing

SEC Form D Funding Events

DateOfferedSoldType
2014-08-29$800,000$800,000Equity
2013-06-17$700,000$525,000Equity
2013-06-04$1,572,500$1,572,500Equity
2013-06-04$849,999$849,999Equity
2010-11-16$1,200,000$872,973Debt, Option to Acquire
2006-11-01Unknown Unknown Other (Paper Filing)

Key Executives

  • Bradley Nyberg
    Director
  • J.Donald Payne
    Executive Officer, Director
  • David Anderson
    Director
  • Jennifer West
    Director
  • Patrick Pace
    Director
  • Glenn Goodrich
    Executive Officer
  • David Bristol
    Director
  • David Jorden
    Executive Officer, Director